Songül Turğut, İskender Samet Dalbatan
The Journal of European Internal Medicine Professionals - 2025;3(4):165-170
Neurological diseases present significant global health challenges due to their high prevalence, substantial disability burden, and previously limited therapeutic options. Recent breakthroughs in neuropharmacology and precision medicine have dramatically advanced treatment paradigms, ushering in targeted medications that alter disease progression, alleviate symptoms, and improve patient quality of life. This review systematically examines recent pharmacological innovations across Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS). For AD, landmark disease-modifying therapies such as aducanumab and lecanemab targeting amyloid pathology, and the introduction of transdermal donepezil, have expanded therapeutic possibilities. In PD, novel formulations like opicapone and sublingual apomorphine provide enhanced control of motor fluctuations. For MS, oral sphingosine-1-phosphate receptor modulators (ozanimod, ponesimod), home-administered B-cell therapies (ofatumumab), novel fumarate formulations (monomethyl fumarate), and optimized monoclonal antibodies (ublituximab) represent significant therapeutic advancements. This review provides clinicians and researchers with comprehensive, structured insights into these novel pharmacotherapies, highlighting their clinical efficacy, dosing considerations, and safety profiles, thereby facilitating informed clinical decision-making and promoting precision medicine in neurology.
